REFERENCES
- Clemmer T, Spulher V. Developing and gaining acceptance for patient care protocols. New Horiz. 1998;6:12–19.
- Verheggen F, Nieman F, Jonkers R. Determinants of pa-tient participation in clinical studies requiring informed consent: Why patients enter a clinical trial. Patient Educ Counsel. 1998;35:111–125.
- Ubel P, Merz J, Shea J, Asch D. How preliminary data affect people's stated willingness to enter a hypothetical randomized controlled trial. J Invest Med. 1997;45:561–566.
- Aby J, Pheley A, Steinberg P. Motivation for participation in clinical trials of drugs for the tratment of asthma, seasonal allergic rhinitis, and perennial nonallergic rhinitis. Ann Al-lergy Asthma Immunol. 1996;76:348–354.
- Tercyak K, Johnson S, Kirkpatrick K, Silverstein J. Offering a randomized trial of intensive therapy for IDDM to adoles-cents. Reasons for refusal, patient characteristics, and recruiter effects. Diabetes Care. 1998;21:213–215.
- Hankins C, Lapointe N, Walmsley S. Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV study group. Can Med Assoc J. 1998;159:1359–1365.
- Koblin B, Heagerty P, Sheon A, et al. Readiness of high risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785–793.
- McQueen K, Vanichseni S, Kitayaporn D, et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:243–251.
- Celentano D, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk popula-tion in northern Thailand. AIDS. 1995;9:1079–1084.
- Bartholow B, MacQueen K, Douglas J, Buchbinder S, McKirnan D, Judson F. Assessment of the changing will-ingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acqur Immune Defic Syndr Human Retrovirol. 1997;16:108–115.
- Hays R, Kegeles S. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Human Retrovirol. 1999;20:164–171.
- Berg M. Problems and promises of the protocol. Social Sci Med. 1997;44:1081–1088.